Clovis Oncology Inc (NASDAQ:CLVS)

5.67
Delayed Data
As of 4:03pm ET
 -0.11 / -1.90%
Today’s Change
4.08
Today|||52-Week Range
11.10
+18.13%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$624.6M

Company Description

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Contact Information

Clovis Oncology, Inc.
5500 Flatiron Parkway
Boulder Colorado 80301
P:(303) 625-5000
Investor Relations:
(303) 625-5023

Employees

Shareholders

Individual stakeholders4.14%
Mutual fund holders26.31%
Other institutional22.48%

Top Executives

Patrick J. MahaffyPresident, Chief Executive Officer & Director
Daniel W. MuehlChief Financial Officer & Executive Vice President
Lindsey RolfeChief Medical Officer & Executive VP-Clinical
Thomas Fuglsang HardingChief Scientific Officer & Executive VP
Gillian C. Ivers-ReadChief Regulatory Officer & Executive VP